Insiders Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 16/04/2026 am IST			5-day change	1st Jan Change
21.73 ^USD	-1.90%		-0.78%	+0.98%

07/04	RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating	MT
26/03	Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating	MT

Insiders

19/03	Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value	CI
04/03	NervGen Pharma Corp. Announces Executive Changes	CI
26/02	Sarepta Therapeutics CEO Ingram to retire by year end	RE
26/02	Douglas Ingram Plans to Retire as Chief Executive Officer of Sarepta Therapeutics, Inc	CI
03/11	Kalaris Therapeutics, Inc. Announces Executive Changes, Effective from November 3, 2025	CI
06/25/06	KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer	MT
03/25/03	Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel	CI
14/25/14	Sarepta Therapeutics, Inc. Announces End of Employment for Bilal Arif as Executive Vice President, Chief Technical Operations Officer, Effective September 16, 2025	CI
09/25/09	Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency	RE
09/25/09	Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency	RE
30/25/30	US FDA's top vaccine official Vinay Prasad leaves agency after 3 months	RE
17/25/17	Sarepta Therapeutics, Inc Announces Management Changes	CI
06/25/06	US FDA names oncologist Vinay Prasad as top vaccine official	RE
31/25/31	Drugmaker shares sink after key FDA official ousted	RE
31/25/31	Pharma stocks sink after ouster of top FDA vaccine regulator	RE
17/24/17	Sarepta Therapeutics Insider Sold Shares Worth $1,310,820, According to a Recent SEC Filing	MT
16/24/16	Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors	CI
20/24/20	Sarepta Therapeutics Insider Bought Shares Worth $4,955,728, According to a Recent SEC Filing	MT
12/24/12	Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	MT
07/24/07	Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	MT
06/23/06	Sarepta Therapeutics Insider Bought Shares Worth $2,001,800, According to a Recent SEC Filing	MT
06/23/06	Sarepta Therapeutics Insider Bought Shares Worth $3,940,500, According to a Recent SEC Filing	MT
15/23/15	Insider Buy: Sarepta Therapeutics	MT
14/23/14	Insider Buy: Sarepta Therapeutics	MT
11/23/11	Insider Buy: Sarepta Therapeutics	MT